The term, and what is actually being described
Patients started using the phrase before doctors did. Someone loses a significant amount of weight on a GLP-1 medication, the body responds exactly as hoped, and then somewhere around the fourth or fifth month a friend says they look tired. Not thinner. Tired.
Dr. Kamen Ng: What they are describing is real, and it is not vanity. The face has lost volume in a pattern that reads to other people as ageing rather than slimming.
It is worth saying plainly at the start that this is a consequence of weight loss itself, not a peculiarity of any one drug, and that the medications involved are prescribed for defined clinical indications after assessment. Nobody should be taking them for their face, and nobody should stop taking one because of their face without speaking to the doctor who prescribed it.
What follows is what we see, why it happens, and the part almost nobody discusses: how much of it can be prevented while it is still happening rather than repaired afterwards.
Why the face changes faster than the body
Dr. Kamen Ng: Facial fat is not a single layer. It sits in discrete compartments, deep and superficial, separated by fibrous septae.
They do not deplete evenly or in the order you would want. The deep medial cheek compartment goes early. So does the temporal fat pad. Both sit under structures that depend on them for support.
When the deep cheek deflates, everything above it loses its platform. The lid-cheek junction lengthens, the tear trough deepens, and the nasolabial fold becomes more defined even though nothing has been added to it. When the temple hollows, the upper face narrows and the brow loses its lateral support.
None of these are new problems. They are the same structures that change over decades, arriving over months.
The skin envelope is the other half of it. Skin retracts, but slowly, and its capacity to do so depends on collagen and elastin that decline steadily from the mid-thirties.
Lose fifteen kilograms at thirty-two and the envelope largely keeps up. Lose the same fifteen at fifty-four and it does not. This is why two patients on identical doses can have completely different faces at the end of it, and why age is a better predictor of the outcome than dose.
The retaining ligaments complete the picture. They stay fixed while the tissue around them changes, so as volume goes, the tethered points become relatively more prominent. The face does not deflate smoothly. It deflates around its anchors.
The variable that matters most, and it is not the dose
Dr. Daniel Chong: Rate. Not total loss, rate.
Weight loss is never purely fat. Some proportion of what comes off is lean tissue, and the faster the loss, the worse that proportion becomes. Rapid loss also gives the skin envelope no time to retract, so you get the two problems compounding: less underlying support, and a covering that has not adapted.
This is the part patients are rarely told.
When someone comes to me in month five distressed about their face, the conversation I wish we had been having is the one about titration speed in month one. A slower climb to the effective dose, with weight tracked against body composition rather than against the scale alone, produces a materially different outcome six months later. The endpoint can be the same. The path changes what you look like when you arrive.
I want to be careful here. Slower is not automatically better for every patient, and the clinical indication comes first. Someone with significant metabolic risk may need the benefit sooner than their face would prefer. That is a judgement made with the prescribing doctor, not a rule.
What we can actually prevent
Dr. Daniel Chong: Most of it, and this is the part that gets no attention because it is unglamorous.
Protecting lean mass protects the face. They are the same problem measured in two places. Three things move that needle, and none of them are treatments.
Protein. Requirements go up during weight loss, not down, and appetite suppression makes hitting them harder precisely when they matter most. Patients who lose weight well on these medications are almost always the ones who kept protein intake deliberate rather than incidental.
Resistance training. Not cardio. Muscle is retained by being loaded. Two or three sessions a week during active loss changes the composition of what comes off, and there is no supplement or infusion that substitutes for it.
Measuring the right thing. A scale cannot tell you whether you are losing fat or muscle. Body composition tracking can, and it turns an invisible problem into a visible one while there is still time to act. At Hayat we run this at baseline and at intervals through the programme, alongside the bloods that matter during rapid loss.
A patient doing those three things loses a different kind of weight from a patient doing none of them, and their face at month eight shows it.
The mistake that costs the most
Dr. Kamen Ng: Treating a face that is still changing.
Someone arrives in month four, unhappy, still losing. We fill the tear troughs and restore the cheeks. Three months later they have lost another eight kilograms, the face beneath the product has moved again, and now the filler sits wrong. So it gets adjusted. Then adjusted again.
This is how the recognisably overfilled face develops: never from a single decision, always from a sequence of reasonable ones taken at the wrong time.
It is also expensive twice over. Money is spent on product that will not sit correctly, and then on dissolving or correcting it.
So our answer to a patient in active weight loss is usually not a treatment plan. It is a photograph, a baseline, and a date to come back. That is a difficult consultation to have when someone is distressed about their appearance, and it is the right one.
How the two clinics actually work together
This is the part we wanted to write down, because we have not seen it described anywhere and it is the whole reason the two practices sit alongside each other.
Phase one, before you start. If we see you before the first injection, this is where most of the value is. Hayat takes a baseline: body composition, relevant bloods, and a conversation about protein and training that will matter more than anything we do later.
AOKLINIK takes standardised facial imaging, so that in eight months there is an objective record rather than a memory and a phone gallery. Almost nobody does this, because almost nobody thinks about their face before they start.
Phase two, during active loss. Hayat's work, and no aesthetic treatment. Composition tracked at intervals, titration adjusted with the prescribing doctor where the rate of lean loss warrants it, protein and resistance training reviewed rather than assumed. If the face is changing quickly, that is information about what is happening underneath, and the response belongs on the metabolic side, not the cosmetic one.
Phase three, stabilisation. Weight steady for around three months. We compare current imaging against the baseline, which usually reframes the conversation: what patients believe they have lost and what they have actually lost are frequently different, and in the temples and the deep cheek it is often worse than they realise while the jawline is better.
Phase four, restoration. Only now. Structure before volume: collagen stimulation to rebuild support over months rather than large filler volumes to replace what deflated, because a rebuilt scaffold ages better than a filled hollow.
Skin quality treated as its own problem, since laxity and texture do not respond to volume. Filler used deliberately and conservatively at the end, where structure alone cannot restore contour.
The sequence is the point. Each phase makes the next one cheaper and better, and skipping to phase four is what produces the results people are unhappy with.
What this cannot fix
Dr. Kamen Ng: True skin laxity has a ceiling, and it sits below surgery.
If the envelope has genuinely lost its capacity to retract, which is more likely with greater loss, older skin and a faster timeline, then energy devices and injectables will improve quality and restore some support, but they will not tighten a face the way a surgical procedure would. We would rather tell you that at the first consultation than after you have spent a year finding out.
Equally, none of this is an argument against the medication. These drugs do things for metabolic health that we could not achieve before, and a face is a poor reason to decline a treatment your doctor has recommended. It is a good reason to plan properly around it.
Frequently asked questions
Partly, and it depends what is driving it. Volume loss can be rebuilt. Skin that has lost elasticity and no longer retracts is a harder problem, and beyond a certain point it has a ceiling below surgery. This is why the prevention side of this matters more than the correction side.
We ask for weight to have been stable for around three months. A face that is still changing will keep changing after treatment, which means paying twice and often looking overfilled in the interim. Waiting is the single most useful thing most patients can do.
It can, if it is placed into a face that is still losing volume, or if large amounts are used to chase deflation rather than rebuild structure. Used conservatively after weight has stabilised, it has a clear role. Sequence and timing matter more than product.
To a meaningful degree, yes. Slower titration, adequate protein, resistance training and monitoring body composition rather than weight alone all reduce how much lean tissue is lost. Less lean loss means less facial loss. That is the Hayat side of this and it is where most of the benefit is available.
The pattern relates to the amount and speed of weight loss rather than to any one product. Semaglutide, marketed as Wegovy and Ozempic, tirzepatide as Mounjaro, and liraglutide as Saxenda all produce it when loss is rapid. All are prescription medicines, prescribed for defined clinical indications after assessment, and never for how a face looks.
Not necessarily. If you are still losing weight, the useful appointment is the metabolic one. If your weight has been stable for months and the concern is your face, the useful appointment is the aesthetic one. Patients who come to us before starting a GLP-1 are the ones we can help most, and they are the minority.
If you are reading this before you start
You are in the minority, and you are the person we can help most. A baseline appointment costs you an hour and changes what is available to you a year from now.
If you are already six months in and unhappy with what you see, that is workable too. It begins with an honest assessment of what has changed and, more often than not, with waiting rather than treating.
This article is general educational information and is not medical advice, a diagnosis, or an offer of treatment. GLP-1 receptor agonists are prescription medicines, indicated and prescribed by a registered medical practitioner following individual assessment, and never for cosmetic reasons. Do not start, stop or alter any prescribed medication without speaking to the doctor who prescribed it. Suitability, technique and outcomes for any aesthetic procedure vary between individuals and no result can be guaranteed.